Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes
Juan P. Frías, Edward J. Bastyr, Louis Vignati, et al.
Cell Metabolism (2017) Vol. 26, Iss. 2, pp. 343-352.e2
Open Access | Times Cited: 285

Showing 1-25 of 285 citing articles:

Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Daniel J. Drucker
Cell Metabolism (2018) Vol. 27, Iss. 4, pp. 740-756
Open Access | Times Cited: 1241
Anti-obesity drug discovery: advances and challenges
Timo D. Müller, Matthias Blüher, Matthias H. Tschöp, et al.
Nature Reviews Drug Discovery (2021) Vol. 21, Iss. 3, pp. 201-223
Open Access | Times Cited: 688
Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
Juan P. Frías, Michael A. Nauck, Joanna Van, et al.
The Lancet (2018) Vol. 392, Iss. 10160, pp. 2180-2193
Closed Access | Times Cited: 658
LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept
Tamer Coşkun, Kyle W. Sloop, Corina Loghin, et al.
Molecular Metabolism (2018) Vol. 18, pp. 3-14
Open Access | Times Cited: 575
Type II diabetes mellitus: a review on recent drug based therapeutics
Santwana Padhi, Amit Kumar Nayak, Anindita Behera
Biomedicine & Pharmacotherapy (2020) Vol. 131, pp. 110708-110708
Open Access | Times Cited: 511
Mechanisms controlling pancreatic islet cell function in insulin secretion
Jonathan E. Campbell, Christopher B. Newgard
Nature Reviews Molecular Cell Biology (2021) Vol. 22, Iss. 2, pp. 142-158
Open Access | Times Cited: 440
G protein-coupled receptors: structure- and function-based drug discovery
Dehua Yang, Qingtong Zhou, Viktorija Labroska, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 425
SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications
Emily Brown, Hiddo J.L. Heerspink, Daniel J. Cuthbertson, et al.
The Lancet (2021) Vol. 398, Iss. 10296, pp. 262-276
Open Access | Times Cited: 383
Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
Francis S. Willard, Jonathan D. Douros, M Gabe, et al.
JCI Insight (2020) Vol. 5, Iss. 17
Open Access | Times Cited: 301
How May GIP Enhance the Therapeutic Efficacy of GLP-1?
Ricardo J. Samms, Matthew P. Coghlan, Kyle W. Sloop
Trends in Endocrinology and Metabolism (2020) Vol. 31, Iss. 6, pp. 410-421
Open Access | Times Cited: 277
Plasma proteome profiling discovers novel proteins associated with non‐alcoholic fatty liver disease
Lili Niu, Philipp E. Geyer, Nicolai J. Wewer Albrechtsen, et al.
Molecular Systems Biology (2019) Vol. 15, Iss. 3
Open Access | Times Cited: 234
Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management
Chengxu Ma, Xiaoni Ma, Conghui Guan, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 227
Advances in therapeutic peptides targeting G protein-coupled receptors
Anthony P. Davenport, Conor C. G. Scully, Chris de Graaf, et al.
Nature Reviews Drug Discovery (2020) Vol. 19, Iss. 6, pp. 389-413
Open Access | Times Cited: 224
Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease
Laurie L. Baggio, Daniel J. Drucker
Molecular Metabolism (2020) Vol. 46, pp. 101090-101090
Open Access | Times Cited: 220
Treatment of type 2 diabetes: challenges, hopes, and anticipated successes
Michael A. Nauck, Jakob Wefers, Juris J. Meier
The Lancet Diabetes & Endocrinology (2021) Vol. 9, Iss. 8, pp. 525-544
Closed Access | Times Cited: 203
Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH)
Xiaohan Xu, Kyle L. Poulsen, Lijuan Wu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 202
Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism
Piotr Mróz, Brian Finan, Vasily M. Gelfanov, et al.
Molecular Metabolism (2018) Vol. 20, pp. 51-62
Open Access | Times Cited: 175
Immunotherapy for cardiovascular disease
Esther Lutgens, Dorothee Atzler, Yvonne Döring, et al.
European Heart Journal (2019) Vol. 40, Iss. 48, pp. 3937-3946
Closed Access | Times Cited: 170
Drug Therapy in Obesity: A Review of Current and Emerging Treatments
David M. Williams, Asif Nawaz, Marc Evans
Diabetes Therapy (2020) Vol. 11, Iss. 6, pp. 1199-1216
Open Access | Times Cited: 166
GIP as a Therapeutic Target in Diabetes and Obesity: Insight From Incretin Co-agonists
Jens J. Holst, Mette M. Rosenkilde
The Journal of Clinical Endocrinology & Metabolism (2020) Vol. 105, Iss. 8, pp. e2710-e2716
Open Access | Times Cited: 146
Effects on weight loss and glycemic control with SAR441255, a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist
Martin Bossart, Michael Wagner, Ralf Elvert, et al.
Cell Metabolism (2021) Vol. 34, Iss. 1, pp. 59-74.e10
Open Access | Times Cited: 124
The expanding incretin universe: from basic biology to clinical translation
Daniel J. Drucker, Jens J. Holst
Diabetologia (2023) Vol. 66, Iss. 10, pp. 1765-1779
Open Access | Times Cited: 117
Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatment
Katherine O. Kopp, Elliot J. Glotfelty, Yazhou Li, et al.
Pharmacological Research (2022) Vol. 186, pp. 106550-106550
Open Access | Times Cited: 114
The neuroprotective effects of glucagon-like peptide 1 in Alzheimer’s and Parkinson’s disease: An in-depth review
Niklas Reich, Christian Hölscher
Frontiers in Neuroscience (2022) Vol. 16
Open Access | Times Cited: 110
Semaglutide for the treatment of overweight and obesity: A review
Natasha C. Bergmann, Melanie J. Davies, Ildiko Lingvay, et al.
Diabetes Obesity and Metabolism (2022) Vol. 25, Iss. 1, pp. 18-35
Open Access | Times Cited: 109
Page 1 - Next Page

Scroll to top